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Abstract 
The contribution of vascular disease to cognitive impairment is under-
recognised and the pathogenesis poorly understood. This information gap has 
multiple causes, including a lack of post-mortem validation of clinical 
diagnoses of vascular cognitive impairment (VCI) or vascular dementia (VaD), 
the exclusion of cases with concomitant neurodegenerative disease when 
diagnosing VCI/VaD, and a lack of standardisation of neuropathological 
assessment protocols for vascular disease. Other contributors include a focus 
on end-stage destructive lesions to the exclusion of more subtle types of 
diffuse brain injury, on structural abnormalities of arteries and arterioles to the 
exclusion of non-structural abnormalities and capillary damage, and the use of 
post-mortem sampling strategies that are biased toward the identification of 
neurodegenerative pathologies. Recent studies have demonstrated the value 
of detailed neuropathology in characterising vascular contributions to 
cognitive impairment (for example, in diabetes), and highlight the importance 
of diffuse white matter changes, capillary damage and vasoregulatory 
abnormalities in VCI/VaD. The use of standardised, evidence-based post-
mortem assessment protocols and the inclusion of biochemical as well as 
morphological methods in neuropathological studies should improve the 
accuracy of determination of the contribution of vascular disease to cognitive 
impairment and clarify the relative contribution of different pathogenic 
processes to the tissue damage. 
 
  
INTRODUCTION 
Pure vascular dementia (VaD) is reported to account for approximately 10-
20% of all cases of dementia [1, 2] but this is likely to represent the tip of the 
iceberg in terms of the contribution of vascular disease to cognitive 
impairment − vascular cognitive impairment (VCI). Most figures on the 
epidemiology of vascular dementia have been based on unvalidated clinical 
assessment. When autopsy data have been available, diagnosis of VaD has 
usually required post-mortem evidence of multiple cerebral infarcts. Cases 
that lack infarcts in the histologically sampled tissue or have concurrent 
neurodegenerative pathology of more than mild severity have usually been 
excluded, without an understanding of the contribution of the various disease 
processes to the cognitive impairment, and resulting in substantial 
underestimation of the prevalence of cognitive dysfunction that has a vascular 
component. The importance of detailed clinicopathological correlation and the 
use of a standardised approach for the post-mortem assessment of vascular 
as well as neurodegenerative abnormalities was highlighted by a recent study 
of the association between diabetes mellitus and cognitive impairment in a 
large (n = 2365) autopsy cohort, in which impaired cognition was found to be 
solely attributable to cerebral small vessel disease (SVD) not Alzheimer's 
disease (AD) pathology in diabetes [3], contrasting with the findings in a range 
of purely clinical studies on the basis of which diabetes was reported to be a 
risk factor for AD [4]. 
Reasons for underestimating the contribution of vascular disease to 
cognitive impairment even in post-mortem studies include a tendency to focus 
on end-stage destructive lesions (e.g. infarcts) to the exclusion of more subtle 
types of damage, on obvious structural abnormalities of the vessel wall (e.g. 
marked arteriolosclerosis and atherosclerosis) to the exclusion of less 
noticeable changes (e.g. reduction in capillary density), and the use of post-
mortem sampling and assessment strategies that are biased toward the 
identification of neurodegenerative pathologies. 
Cerebral perfusion may be compromised at multiple levels: cardiac, 
arterial, arteriolar and capillary, and the underlying cardiovascular abnormality 
may be sustained or intermittent, structural or regulatory/non-structural. In 
general, sustained hypoperfusion results from structural cardiovascular 
disease and intermittent hypoperfusion reflects abnormal regulation of cardiac 
output or cerebral vascular tone. However, the distinction is not clear-cut: 
structural diseases such as cerebral amyloid angiopathy (CAA) can interfere 
with neurovascular coupling, and some regulatory abnormalities cause 
chronic mismatch between metabolic demand and blood supply. 
In this review we consider what is known, particularly from studies on 
human brain tissue, about the timing, causes and consequences of arteriolar 
and capillary compromise in VCI/VaD (and also AD and mixed dementia 
where the information is relevant to an understanding of VCI/VaD), and what 
key questions remain to be answered. In keeping with the theme of this issue 
of Clinical Science, the review does not cover disease of larger arteries, major 
stroke or cardiac disease, except in the context of mechanisms of brain 
damage that are shared with intracerebral vascular disease. Also excluded 
from this review are inherited vasculopathies such as CADASIL. 
 TIMING OF ARTERIOLAR AND CAPILLARY COMPROMISE IN VCI AND 
VAD 
There is a paucity of information on the timing of development of changes in 
vascular structure and function in VaD. 
 
Clinical predictors 
Several clinical and MRI features predict the development of VaD [5-12]. 
These include a history of hypertension, hypertension, heart disease, diabetes 
mellitus, transient ischaemic attacks (TIAs) and stroke; executive dysfunction, 
gait disturbances, urinary incontinence or personality changes, often in the 
absence of memory problems; and white matter hyperintensities or infarcts, 
often with relative preservation of temporal lobe volume. The prodromal 
clinical stage is termed vascular-mild cognitive impairment (VMCI), defined by 
the presence of mixed domains of cognitive impairment other than of memory 
(although memory impairment may also be present), in someone with a 
personal or family history of TIAs, strokes (clinically manifest or silent), with 
strong risk factors for stroke and without a family history of neurodegenerative 
dementia [5, 8-10]. Over half of patients who develop VaD have preceding 
VMCI, and about two-thirds of VMCI patients have MRI changes of non-
amyloid SVD (NA-SVD) rather than strategic-infarct dementia [5, 8]. It seems 
very likely therefore that most VMCI patients will therefore have had moderate 
or marked arteriolosclerosis for some years before they develop dementia. 
 
NA-SVD risk factors versus associations 
The general presumption is that cerebral NA-SVD is a consequence of 
genetic, lifestyle and environmental factors that include cigarette smoking, 
hypertension, diabetes and age [13, 14]. However, these account for only a 
small proportion of the attributable risk of NA-SVD. In addition, we should 
consider the possibility of reverse causality as far as hypertension is 
concerned, i.e. the possibility that NA-SVD may cause or contribute to the 
development of hypertension in some people. SVD impairs cerebral perfusion. 
There is a highly significant negative correlation between the severity of 
arteriolosclerosis in the cerebral white matter and markers of tissue 
oxygenation [15, 16]. Elevation of cerebral perfusion pressure, manifesting as 
systemic hypertension, would be expected as a protective physiological 
response to reduced arteriolar calibre and impaired cerebral oxygenation [17, 
18]. In a large clinical study, Warnet et al. [18] showed that (i) people with 
hypertension were more likely to have congenital variants of the circle of Willis 
that were associated with increased cerebral vascular resistance, reduced 
cerebral blood flow and a higher incidence of lacunar infarcts, (ii) cerebral 
vascular resistance was elevated before the onset of hypertension and 
elevated sympathetic nerve activity, and (iii) cerebral blood flow was normal in 
untreated hypertensive patients but reduced in patients receiving 
antihypertensive medication. 
These observations suggest that hypertension may in some people be 
mediated by increased sympathetic activity secondary to cerebral 
hypoperfusion, causes of which would include SVD. Mid-life hypertension is 
also associated with (and assumed to be a risk factor for) AD [19, 20]. 
However, intracerebral accumulation of Aβ, like arteriolosclerosis, is 
associated with hypoperfusion and reduced tissue oxygenation [15, 21, 22], 
and we have shown that cerebroventricular infusion of Aβ induces or 
exacerbates hypertension in Dahl rats [23]. Together these clinical and 
experimental studies suggest that cerebral hypoperfusion as a result of 
vascular disease, whether structural such as arteriolosclerosis or abnormal 
regulation of vascular tone as in AD, may cause or contribute to hypertension. 
Of course, these observations do not preclude hypertension itself as a 
contributor to NA-SVD and raise the possibility of a vicious cycle in which 
hypertension initiated by cerebral arteriolosclerosis exacerbates NA-SVD until 
decompensation occurs and cerebral perfusion can no longer be maintained. 
 
Cerebral infarcts 
In several autopsy studies, the presence or severity of cognitive impairment 
was associated with the number and distribution of microinfarcts and/or 
lacunar infarcts (see, for example [24-27]). In the Honolulu Asia Aging 
Autopsy Study, microinfarcts were associated with cognitive function even in 
the absence of dementia [25]. It is noteworthy that this association seemed to 
be mediated through reduction in brain weight. Whilst the microinfarcts may 
have made some direct contribution to the reduction in brain weight, it seems 
likely that they are focal markers of more diffuse ischaemic brain damage. A 
recent autopsy study included 343 people who had had a formal diagnosis of 
MCI or a Clinical Dementia Rating global score of 0.5 within two years of 
death [28]. Tangle and neuritic plaque pathology, and moderate to severe 
vascular pathology (arteriolosclerosis, CAA and lacunar infarcts) were 
relatively common in this group, and most brains had mixed pathology. 
However, the pathological findings that discriminated between individuals and 
those without cognitive impairment were neurofibrillary tangles, neuritic 
plaques, Lewy body pathology, hippocampal sclerosis and arteriolosclerosis – 
not microinfarcts, lacunar infarcts or larger infarcts. 
Skrobot et al. [29] performed blinded post-mortem assessment of brain 
tissue from 113 individuals without significant neurodegenerative disease who 
had had formal cognitive assessments within 12 months of death. Whereas 
leptomeningeal CAA, large infarcts, lacunar infarcts, microinfarcts, 
arteriolosclerosis, perivascular space dilation and myelin loss were all 
individually associated with cognitive impairment, most of these associations 
were no longer significant on multivariable logistic regression analysis: only 
leptomeningeal CAA, at least one large infarct, and either myelin loss or 
arteriolosclerosis in the occipital white matter were retained in the statistical 
model that predicted cognitive impairment (see PATHOLOGICAL 
CONSEQUENCES RELEVANT TO VCI/VAD, below. 
Together these studies indicate that infarcts (particularly lacunar infarcts 
and microinfarcts) are present in a sizable proportion of people with MCI and 
suggest that they often antedate cognitive decline, but that lacunar infarcts 
and microinfarcts unlikely themselves to be directly responsible for the 
cognitive decline in most cases but serve rather as markers of cerebral 
hypoperfusion that causes cognitive decline through more diffuse brain 
damage. 
 
Microbleeds 
The detection of 'microbleeds' on MRI, particularly if numerous, is associated 
with cognitive impairment [30-34] and predicts cognitive decline [35, 36]. Both 
lobar and deep microbleeds are associated with cognitive decline but the 
underlying vascular pathology probably differs according to the location of the 
bleeds, as do the mechanisms of cognitive impairment. Lobar microbleeds are 
associated with clinical and MRI evidence of Aβ-related small vessel disease 
(cerebral amyloid angiopathy, CAA), Aβ deposition and possession of APOE 
ϵ4 [37-42]. Many of those with lobar microbleeds have concomitant AD 
pathology, and this is reflected in the pattern of their cognitive impairment, 
which tends to affect verbal and visuospatial memory. Microbleeds are about 
twice as prevalent in AD patients (24-29%) as in age-matched controls (12%) 
[43-45]. It is unclear whether they are independently associated with cognitive 
decline in AD [43-45]. Although they are often in a predominantly lobar 
distribution, about 30-40% are non-lobar, suggesting concomitant NA-SVD 
[46, 47]. This is in keeping with imaging and pathological studies reporting 
that AD patients have an increased prevalence of ischaemic parenchymal 
abnormalities in a distribution suggestive of NA-SVD. 
Deep microbleeds, particularly those in the thalamus and basal ganglia, 
are associated with white matter hyperintensities, deep infarcts and 
microinfarcts, retinal arteriopathy, elevated blood pressure, and smoking [34, 
37, 48]. Patients with deep microbleeds are more likely than age-matched 
controls to show impairment of global cognitive function, psychomotor speed, 
attention and calculation, and gait [30-32, 41, 49, 50], i.e. a clinical profile 
typical of VCI. 
Post-mortem studies have shown marked heterogeneity in the 
pathological substrate of microbleeds. Some are foci of recent or old 
microhaemorrhage involving the perivascular parenchyma, others are clusters 
of erythrocytes or haemosiderin-laden macrophages in the perivascular 
space, microinfarcts, or foci of fibrinoid necrosis (Figure 1(A-C)) [51-54]. Most 
are related to arterioles or capillaries. 
 
Lack of information on other preclinical vascular abnormalities 
In summary, imaging and post-mortem studies indicate that VMCI is usually 
associated with moderate or marked arteriolosclerosis, and often with 
microhaemorrhages and microinfarcts in the thalamus and basal ganglia. 
Unfortunately scant neuropathological data are available on other preclinical 
structural vascular abnormalities (e.g. affecting capillary endothelium or 
pericytes) or alterations in vascular function (e.g. regulation of vessel calibre 
or permeability), and we have little information on the timing of vascular 
abnormalities in relation to the development of clinical disease. It should be 
noted too that vascular pathology is rarely the sole abnormality in people with 
MCI, most of whom have mixed neurodegenerative and vascular pathology 
[28]. 
 
CAUSES OF ARTERIOLAR AND CAPILLARY COMPROMISE IN VCI AND 
VAD 
At brain tissue level, multiple processes contribute to the development of VCI 
and VaD. Ischaemic parenchymal damage is the main cause of VCI or VaD 
even in people with numerous microbleeds on MRI [52, 53], although 
inflammation and oxidative stress (e.g. induced by myeloperoxidase and 
NADPH oxidase activity, and by the formation of hydroxyl radicals through the 
Fenton reaction) may play a part. Of the various forms of ischaemic 
pathology, diffuse damage to cerebral white matter is probably a particularly 
important cause of cognitive impairment (see Pathological consequences 
relevant to VCI/VaD, below). 
 
Arteriolar changes 
NA-SVD and CAA are associated with narrowing of arteriolar lumina, reducing 
vascular conductance. There is also collagenous thickening of the vessel wall 
in NA-SVD and loss of smooth muscle cells in both NA-SVD and CAA − 
alterations likely to contribute to impaired neurovascular coupling in stroke 
patients and people with hypertension [55, 56] and in those with moderate or 
severe CAA [57, 58]. CAA is mainly associated with ischaemic cortical 
damage [24, 59, 60] but can also contribute to diffuse white matter injury, 
particularly when the Aβ in the vessel walls elicits an inflammatory reaction 
[61, 62].  
 
Pericytes and capillaries 
Pericytes are important for maintenance of the blood-brain barrier (BBB) and 
for regulation of perfusion and neurovascular coupling at capillary level.[63-
67] Degeneration of pericytes is associated with hypoperfusion in the cerebral 
cortex. This was demonstrated in mice deficient in platelet-derived growth 
factor receptor-β which show marked loss of pericytes with age [63, 68], and 
also in cerebral cortex from non-demented elderly people and even more so 
in those with cognitive impairment or AD [63, 69]. In parietal white matter 
hypoperfusion and BBB leakage were not associated with pericyte loss [69] 
but it is possible that more subtle forms of pericyte damage and dysfunction 
may occur in the white matter in VCI and VaD. 
There is a paucity of information on capillary integrity or loss in VCI and 
VaD. One way to gauge the density of capillaries is to measure the level of 
von Willebrand factor, which we showed to correlate closely with conventional 
morphometric quantification of capillary density [22, 70]. We found the level of 
von Willebrand factor to be significantly reduced in frontal white matter from 
people with severe NA-SVD [15], suggesting that NA-SVD causes 
hypoperfusion not only through structural and non-structural alterations in 
vessel calibre but also through loss of capillaries, at least in the white matter. 
 
Vasoregulation 
Neurochemical abnormalities affecting vasoregulation are well-documented in 
dementia, particularly AD, and have the potential to cause diffuse white matter 
ischaemic damage. There is an elevated level of the vasoconstrictor 
endothelin-1 (EDN1) [15, 22, 71], which acts on vascular smooth muscle and 
pericytes to cause vasoconstriction at both arteriolar and capillary level 
(Figure 2(A-C)) [72-74]. The increase in EDN1 is probably mediated by 
elevated expression of endothelin-converting enzymes 1 and 2, which 
catalyse the production of EDN1; these enzymes are upregulated in vitro by 
Aβ40 and Aβ42 respectively, and also in post-mortem cerebral cortex from 
patients with AD [75-77]. Activity of angiotensin-converting enzyme (ACE), 
which catalyses production of another vasoconstrictor, angiotensin II, is 
elevated in frontal cortex in AD [78, 79]. We did not find evidence of 
overproduction of angiotensin II within the white matter in AD or VaD [15, 71] 
but it would be of interest to examine the cerebral renin-angiotensin system in 
more detail in VaD, including within the cerebral cortex. It is important to bear 
in mind that most of the blood that perfuses the subcortical white matter is 
conveyed through perforating arterioles that traverse the cerebral cortex and 
that may therefore be affected by intracortical disease processes [13, 21]. We 
obtained circumstantial evidence that this plays a part in hypoperfusion of the 
white matter in AD (Figure 3): the reduction in oxygenation of white matter, 
measured by the increase in vascular endothelial growth factor (VEGF) and 
the decline in the ratio of myelin-associated glycoprotein (MAG) to proteolipid 
protein-1 (PLP1), was directly related to the levels of Aβ42 and EDN1 in the 
overlying cerebral cortex [71]. Reduced transcortical perfusion presumably 
also contributes to white matter damage in severe CAA, in which the vascular 
disease process is largely restricted to the cortex and overlying 
leptomeninges, and seems likely to do so in NA-SVD. 
 
Blood-brain barrier 
Loss of BBB integrity has the potential to damage both grey and white matter 
by multiple mechanisms. These include leakage of neurotoxic proteins such 
as fibrinogen [63, 80-83], induction of inflammation [80-82], and impaired 
clearance of toxic brain metabolites including Aβ [63]. Several neuroimaging 
studies have found evidence of blood-brain barrier (BBB) damage in NA-SVD 
and VCI [84-87]. Neuropathological studies of the leakage of relatively large 
molecules such as fibrinogen and IgG have yielded inconsistent findings (see 
[88] for discussion). We measured fibrinogen content in post-mortem brain 
tissue by ELISA and found the level to be increased in parietal grey and white 
matter in AD [69]; in both regions fibrinogen content correlated with the 
severity of the perfusion deficit (as evidenced by elevation of VEGF and 
reduction in MAG:PLP1). These findings in human brain tissue are in keeping 
with observations by Zlokovic and others in mice deficient in platelet-derived 
growth factor receptor-β [63, 68]. We have preliminary (unpublished) data 
indicating that there is also fibrinogen leakage in moderate to severe NA-SVD, 
and work is in progress to assess the relationship of the BBB damage to 
tissue oxygenation and integrity. 
 
Failure of vascular homeostasis 
Whilst we are beginning to understand the contribution of different vascular 
cell types and biochemical pathways to the regulation of blood flow and tissue 
oxygenation, and to identify abnormalities in the different cells and pathways 
in VCI and VaD, we still lack a clear understanding of the aetiology of many of 
those abnormalities. There are several examples of failures of vascular 
homeostasis in association with reduced cerebral oxygenation in dementia, as 
illustrated by the dissociation between VEGF level and microvessel density in 
the white matter in NA-SVD [15, 16], and between the level of platelet-derived 
growth factor and pericyte content in the cerebral cortex AD [69]. If we are to 
prevent or treat VCI, VaD and mixed dementia, much more work is needed to 
establish the underlying vascular abnormalities in these diseases, why they 
occur, and which pathogenic processes might be modifiable. 
 
PATHOLOGICAL CONSEQUENCES RELEVANT TO VCI/VAD 
In addition to the obvious focal destructive effects of infarcts and foci of 
haemorrhage, there is increasing appreciation of the more widespread or 
remote damage to neurons [89], synapses [90] and white matter tracts [91-95] 
in VCI and VaD. Cortical disconnection as a result of diffuse damage to 
cerebral white matter that affects the integrity of cortical association fibres and 
subcortical tracts seems to be a particularly important contributor to cognitive 
decline [91, 93, 96]. This is likely to be relevant to cognitive impairment in 
neurodegenerative as well as vascular disease, partly because neuronal 
degeneration leads to axonal loss but also because cerebral hypoperfusion is 
an intrinsic component of AD and Lewy body disease (see Vasoregulation, 
above). Diffuse white matter damage is well demonstrated by diffusion tensor 
MRI but difficult to assess and quantify histologically. However, there is some 
pathological evidence of the important contribution of ischaemic white matter 
damage to cognitive impairment [97, 98]. 
In the multicentre neuropathological study by Skrobot et al. [29] of 
cognitive impairment in the absence of significant neurodegenerative disease, 
the histological variables that correlated best with ante-mortem cognitive 
impairment (combined predictive accuracy of 77-78%) were moderate-to-
severe occipital leptomeningeal CAA, at least one large (> 10 mm diameter) 
infarct, and either moderate-to-severe myelin loss in at least one brain region 
or moderate-to-severe arteriolosclerosis in the occipital white matter. These 
findings were incorporated into a set of vascular cognitive impairment 
neuropathology guidelines (VCING) for assessing of the likely contribution of 
vascular pathology to cognitive impairment. Although VCING represent a 
major advance in our ability to assess the contribution of vascular pathology 
to cognitive impairment, the study had several limitations. Some pathologies 
(e.g. fibrinoid necrosis) were too rare for meaningful analysis. In addition, by 
excluding brains from people with significant neurodegenerative disease, in 
whom the threshold at which vascular pathology contributes to cognitive 
impairment may be reduced, the VCING study may have underestimated the 
contribution of vascular disease to cognitive impairment in the general 
population. The VCING model needs to be validated in an independent large 
cohort, and in the context of mixed neurodegenerative and vascular disease. 
It is also worth emphasizing that the guidelines are largely an indirect 
approach to assessing vascular brain damage; most of the abnormalities that 
are scored in this scheme are not themselves directly responsible for 
cognitive impairment. In particularly, occipital CAA and white matter 
arteriolosclerosis are likely to be markers/proxy indicators of ischaemic white 
matter damage. A more sensitive and specific approach to post-mortem 
determination of the contribution of vascular disease – and more specifically 
hypoperfusion − to cognitive impairment may come from adjunctive 
biochemical studies, in which ischaemic white matter damage can be 
measured biochemically [94]. Our expectation is that the use of biochemical 
as well as morphological methods for post-mortem assessment, in 
combination with efforts to identify better in vivo biomarkers and more specific 
clinical indicators of VCI, will not only improve the accuracy of determination 
of the contribution of vascular disease to cognitive impairment but also will 
also clarify the relative contribution of different pathogenic processes to the 
tissue damage and facilitate the identification of therapeutic targets. 
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Figures 
 
Figure 1. Pathological abnormalities reported to underlie microbleeds.  
(A) Region of old microhaemorrhage, associated with accumulation 
of haemosiderin in the perivascular parenchyma and vessel wall. 
(B) Larger cluster of haemosiderin-laden macrophages, with more 
sparsely distributed accumulations of haemosiderin in the adjacent 
parenchyma. (C) Focus of fibrinoid necrosis in a cortical arteriole 
(note that this patient did not have CAA). 
 
 
Figure 2. Abnormal cerebral perfusion in association with 
vasoconstriction. 
(A) This schematic diagram illustrates a normal capillary bed, fed 
by the arteriole on the left and draining into the venule on the right. 
Vascular smooth muscle cells are represented as yellow bands and 
pericytes are coloured green. (B) Elevated production of 
vasoconstrictors such as endothelin-1 (EDN1) causes contraction 
of smooth muscle cells and pericytes. This reduces blood flow and 
slows the transit of blood through arterioles and capillaries, causing 
oxygen desaturation. (C) In the cerebral cortex in Alzheimer's 
disease there is also some loss of pericytes, and reduced 
oxygenation reflects a combination of cortical hypoperfusion and 
impaired neurovascular regulation. 
 
 
Figure 3. Vascular disease in the cerebral cortex affects perfusion of the 
cerebral white matter. 
Perforating arterioles that arise from meningeal branches of the 
major cerebral arteries supply both the cerebral cortex and the 
underlying white matter. Excessive vasoconstriction within the 
cerebral cortex in Alzheimer's disease (AD) affects not only cortical 
arterioles but also perforating arterioles that traverse the cortex. 
Reproduced from [13, 14]. 
